New directions in the management of advanced pancreatic cancer: a review

@article{RochaLima2008NewDI,
  title={New directions in the management of advanced pancreatic cancer: a review},
  author={Caio Max S Rocha-Lima},
  journal={Anti-Cancer Drugs},
  year={2008},
  volume={19},
  pages={435-446}
}
Complete surgical resection is the only potentially curative option for pancreatic cancer. However, most patients have advanced/metastatic disease at the time of diagnosis, or will relapse after surgery. Systemic chemotherapy is only palliative. Gemcitabine-based therapy is an acceptable standard for unresectable locally advanced/metastatic pancreatic cancer, but average median survival is only 6 months. The addition of other chemotherapies (including other antimetabolites, platinum, and… Expand
Combinational therapy: new hope for pancreatic cancer?
TLDR
Regional intra-arterial chemotherapy achieves higher local drug concentration in tumors with lower systemic drug toxicity, and may serve as a better treatment regimen for advanced pancreatic cancer. Expand
Pancreatic Cancer Treatment
TLDR
Current and future clinical trials using natural compounds such as vitamin E compound delta-tocotrienol and curcumin in combination with standard chemotherapy are ongoing to discover more effective ways of treating advanced pancreatic cancer. Expand
Emerging drugs in the treatment of pancreatic cancer
TLDR
The aims of this review are to define the existing treatments available at present for patients with pancreatic cancers in the neo-adjuvant, adjuvant, locally advanced and metastatic settings, and to highlight the molecular heterogeneity of the cancers and the rationale for targeting specific oncogenic pathways. Expand
Management of advanced pancreatic cancer
TLDR
Despite the benefit of gemcitabine, most patients with advanced disease still do poorly, with a median time-to-tumor progression between 2 and 3 months and median overall survival of 4–6 months. Expand
The role of radiotherapy in locally advanced pancreatic carcinoma
TLDR
The benefits associated with local therapies, including radiotherapy and surgical resection, as they relate to improved local disease control, prolonged overall survival and improved symptom control are focused on. Expand
Challenges in developing targeted therapy for pancreatic adenocarcinoma
TLDR
The molecular heterogeneity typical of pancreatic cancers is described and targeted therapies in development are discussed, suggesting that targeting multiple oncogenic pathways using novel targeted therapies could improve patient survival. Expand
Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
TLDR
Clinical data for HDACIs in patients with pancreatic cancer are inadequate, because only a few studies have included patients suffering from this type of neoplasm and the number of Pancreatic cancer patients that entered HDACI phase II/III trials, among others with advanced solid tumors, is very limited. Expand
An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
TLDR
The antiendothelial agent EMAP II enhanced gemcitabine-mediated tumor inhibition, pointing toward a promising strategy for improved combination treatment of pancreatic cancer. Expand
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
TLDR
The recently described isolation of TICs from hMPM, the proposed main pharmacological target for novel antitumoural drugs, may contribute to better dissect the biology and multidrug resistance pathways controlling hM PM growth. Expand
Current evidence for histone deacetylase inhibitors in pancreatic cancer.
TLDR
HDACIs constitute a promising treatment for pancreatic cancer with encouraging anti-tumor effects, at well-tolerated doses, as well as their antiproliferative effects in animal models are presented. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 113 REFERENCES
Combined modality therapy for pancreatic cancer.
TLDR
According to several phase II trials and Gastrointestinal Tumor Study Group results, improvements in locoregional control and survival may be achieved when chemotherapy is added to radiation for locally advanced pancreatic cancer. Expand
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
TLDR
The results support the use of gemcitabine as adjuvant chemotherapy in resectable carcinoma of the pancreas by significantly delayed the development of recurrent disease after complete resection of pancreatic cancer compared with observation alone. Expand
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
TLDR
Evidence of a dose response for marimastat in patients with advanced pancreatic cancer is provided, and both agents were well tolerated, although grade 3 or 4 toxicities were reported in 22% and 12% of the gemcitabine- and marimaston-treated patients, respectively. Expand
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
TLDR
To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. Expand
Phase II trial of capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma.
TLDR
The combination of CAP and OX is reasonable and tolerable treatment of pancreas cancer with activity even in pts receiving second line chemotherapy. Expand
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
TLDR
It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU. Expand
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
TLDR
Cetuximab in combination with gemcitabine showed promising activity against advanced pancreatic cancer. Expand
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
  • H. Kindler, G. Friberg, +8 authors E. Vokes
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
The combination of bevacizumab plus gemcitabine is active in advanced pancreatic cancer patients, and the response rate and overall survival of patients who received gem citabine with the recombinant humanized anti-VEGF monoclonal antibody was assessed. Expand
Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
  • Medicine
  • Cancer
  • 1987
TLDR
Based on the original study and the confirmatory findings, the combined use of radiation therapy and fluorouracil as adjuvant therapy after curative resection is effective and is preferred to no adjUvant therapy. Expand
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
TLDR
In patients with pancreatic cancer, the combination of GEM with CAP is an active and well tolerated regimen that merits further evaluation in prospective randomized studies. Expand
...
1
2
3
4
5
...